Radiation Oncology

University of Wisconsin

Questions discussed in this category

For locally advanced rectal cancer, would you consider utilizing the RAPIDO trial approach of short course radiation followed by neoadjuvant chemotherapy prior to surgery?

Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.

5 Answers available

In patients with inflammatory bowel disease with low rectal cancer with planned proctocolectomy, would you consider creation of a pouch?

1 Answer available

How should our selection for neoadjuvant chemotherapy for breast cancer change in light of COVID-19?

2 Answers available

Would you consider chemo-radiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?

4 Answers available

When do you consider total neoadjuvant therapy (chemotherapy and chemoradiation) for rectal cancer?

1 Answer available

What is the role of neoadjuvant breast radiation in patients with triple negative breast cancer progressing on AC-T?

Pt clinically has inflammatory breast cancer making mastectomy a poor option.

1 Answer available

Papers discussed in this category

J. Clin. Oncol., 2020 Feb 27

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Lancet Oncol., 2020 Feb 14

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Lancet Oncol, 2020 Dec 07

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

Ann Oncol,

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Lancet Oncol, 2021 Apr 13

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Related Topics in Radiation Oncology